Form 4: Apellis Pharmaceuticals Director Paul Fonteyne Reports Stock and Option Transactions

Director Paul Fonteyne reports acquisition of restricted stock units and stock options in Apellis Pharmaceuticals on January 1, 2025.

Summary

• Paul Fonteyne, a director of Apellis Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On January 1, 2025, Fonteyne acquired 6,267 shares of common stock through restricted stock units and disposed of 0 shares.
• Following the transaction, Fonteyne beneficially owns 22,705 shares of common stock.
• Fonteyne also acquired options to purchase 11,199 shares of common stock at an exercise price of $31.91 on January 1, 2025.
• These options vest quarterly and expire on December 31, 2032.
• The restricted stock units fully vest on the first anniversary of the grant date, contingent on continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option transactions. The acquisition of shares by a director is generally viewed as a slightly positive sign.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of stock and options is tied to continued service as a director.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates director Fonteyne's ongoing investment in Apellis Pharmaceuticals.

Stakeholder Impact

• Shareholders may view the director's stock and option acquisitions as a sign of confidence in the company's future.

Key Dates